The aim of this project is to study the different diagnostic, predictive, and prognostic profiles, as well as their interrelationships (clinical, biological, genetic) in children with Acute Myeloid Leukemia (AML). Despite numerous research projects on separate cohorts, the prognosis for pediatric AML has not improved.
The project therefore consists of pooling research data and existing clinical and biological data from healthcare in a health data warehouse to increase its power.
As these diseases are rare and genetic subgroups even rarer, it is crucial to combine all these data sets into a single database to statistically validate our observations.
The ultimate goal of this project is to reduce the relapse rate and improve the survival rate of pediatric AML by identifying rare, uncharacterized patient subgroups at high risk of relapse, for whom clinical characteristics and outcomes will be compared with omics data, Leukemia Stem Cells signatures, and drug responses to establish accurate and in-depth profiles.
None
None
Patients already included in a protocol or newly included
Cohort
Cross-sectional
Long term follow-up
Other interventionLong term follow-up as part of standard of care
Overall survival
Event Free Survival
Event is defined as : relapse, secondary cancer
Cumulative incidence of relapse
Cumulative incidence of second cancer
Incidence of long-term sequelae
Heart failure, kidney failure, endocrine failure, or any other medical condition covered at 100% by French Social Security
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
